Stage III Renal Cell Cancer Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0028847 (Stage III Renal Cell Cancer)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03260504Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney CancerTreatment